Focus Partners Wealth
RXRX icon

Focus Partners Wealth’s Recursion Pharmaceuticals RXRX Stock Holding History

Focus Partners Wealth’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,555
Closed -$90.5K – 2776
2025
Q3 		$90.5K Buy
18,555
+4,215
+29% +$22.1K ﹤0.01% 2131
2025
Q2 		$72.6K Sell
14,340
-214
-1% -$1.05K ﹤0.01% 1961
2025
Q1 		$77K Buy
+14,554
New +$106K ﹤0.01% 1823

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Focus Partners Wealth's RXRX Position: Q4 2025 in Review

Focus Partners Wealth sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 18,555 shares — an estimated $90.5K sold.

Focus Partners Wealth first reported a position in RXRX in Q1 2025 and held it in 3 quarters. The position peaked at $90.5K in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Focus Partners Wealth reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 18,555 Recursion Pharmaceuticals shares in Q4 2025, an estimated $90.5K.
  • Focus Partners Wealth first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Focus Partners Wealth's Recursion Pharmaceuticals position peaked at $90.5K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Focus Partners Wealth's 13F filing for Q4 2025, filed 13 Feb 2026.